| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Klinik und Poliklinik für Nuklearmedizin der Ludwig-Maximilians-Universität München, München, Germany
The objective of this prospective study was to determine the extent to which the levels of thyroid-stimulating hormone (TSH) influence the uptake of FDG by thyroid carcinoma tumors Methods: Ten patients with follicular (n = 7) or papillary (n = 3) thyroid carcinoma underwent FDG PET during TSH suppression (<0.05 µU/mL) and TSH stimulation (>22 µU/mL) within an average interval of 42 d (range, 28–73 d). The findings were evaluated by visual criteria. In addition, a tumor-to-background ratio (TBR) was determined for 17 lesions that were visualized. Results: In 15 of 17 lesions with positive FDG uptake, TSH stimulation was associated with an increase in the TBR from 3.85 ± 2.53 (mean ± SD) to 5.84 ± 4.84, corresponding to an average increase of 63.1% (P < 0.001). Determination of absolute counting rates indicated that this increase was the result of a decrease in FDG metabolism in the background together with an increase in the tumor tissue. No relationship was found between the presence or absence of iodine storage capacity (5 versus 12/17 lesions) and increase in FDG accumulation. Seven of 10 patients had additional iodine-positive metastases that showed no accumulation of FDG. Conclusion: Most locally recurrent and metastatic follicular and papillary thyroid carcinomas exhibited a significant increase in FDG uptake on TSH stimulation. In 3 of 10 patients, TSH stimulation resulted in either detection of new lesions or classification of the FDG uptake pattern as typical for malignancy. These findings suggest that FDG uptake in recurrent and metastatic thyroid carcinoma depends on the TSH level. Therefore, we recommend that PET examinations be performed in patients with thyroid carcinoma under TSH stimulation and follow-up examinations be performed under identical TSH conditions to prevent erroneous interpretation.
Key Words: FDG PET • thyroid-stimulating hormone • thyroid carcinoma
Received Aug. 12, 1999; revision accepted Dec. 29, 1999.
For correspondence or reprints contact: Florian Moog, MD, Department of Nuclear Medicine, Ludwig-Maximilians-Universität München, Marchionini-Strasse 15, D-81366 München, Germany.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  S. Leboulleux, P. R. Schroeder, N. L. Busaidy, A. Auperin, C. Corone, H. A. Jacene, M. E. Ewertz, C. Bournaud, R. L. Wahl, S. I. Sherman, et al. Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1310 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Blaser, S. Maschauer, T. Kuwert, and O. Prante In Vitro Studies on the Signal Transduction of Thyroidal Uptake of 18F-FDG and 131I-Iodide J. Nucl. Med., August 1, 2006; 47(8): 1382 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Lee, H.-K. Kim, J.-Y. Paik, T. Matsui, Y. S. Choe, Y. Choi, and B.-T. Kim Accuracy of Myocardial Sodium/Iodide Symporter Gene Expression Imaging with Radioiodide: Evaluation with a Dual-Gene Adenovirus Vector J. Nucl. Med., April 1, 2005; 46(4): 652 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, and P. Ladenson Recombinant Human Thyrotropin Stimulation of Fluoro-D-Glucose Positron Emission Tomography Uptake in Well-Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 91 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Spieth, S. B. Standiford, M. E. Starkman, and J. Gough Recombinant TSH-Stimulated, Radioguided Differentiated Thyroid Carcinoma Surgery Clin. Med. Res., January 1, 2003; 1(1): 53 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mruck, A. Pfahlberg, T. Papadopoulos, C. Stremmel, and T. Kuwert Uptake of 201Tl into Primary Cell Cultures from Human Thyroid Tissue Is Multiplied by TSH J. Nucl. Med., February 1, 2002; 43(2): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hooft, O. S. Hoekstra, W. Deville, P. Lips, G. J. J. Teule, M. Boers, and M. W. van Tulder Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3779 - 3786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grunwald and H.-J. Biersack FDG PET in Thyroid Cancer: Thyroxine or Not? J. Nucl. Med., December 1, 2000; 41(12): 1996 - 1998. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
